How Much Longer Will We Put Up With $100,000 Cancer Drugs?
Files
Publication date
2017-02-09
Authors
Workman, Paul
Draetta, Giulio F
Schellens, Johannes
Bernards, René
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
The spiraling cost of new drugs mandates a fundamentally different approach to keep lifesaving therapies affordable for cancer patients. We call here for the formation of new relationships between academic drug discovery centers and commercial partners, which can accelerate the development of truly transformative drugs at sustainable prices.
Keywords
Antineoplastic Agents, Drug Approval, Drug Costs, Drug Discovery, Health Care Costs, Humans, Neoplasms, United States, Journal Article, SDG 3 - Good Health and Well-being
Citation
Workman, P, Draetta, G F, Schellens, J H M & Bernards, R 2017, 'How Much Longer Will We Put Up With $100,000 Cancer Drugs?', Cell, vol. 168, no. 4, pp. 579-583. https://doi.org/10.1016/j.cell.2017.01.034